Castleman disease · 9 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Siltuximab monotherapy Variant #01 | — | R 75 219 | 21d | — | — | ~2 | ~R 150 438 indirect | — |
Cyclosporine monotherapy Variant #03 | — | R 29 855 | — | — | — | ~1 | ~R 29 855 indirect | — |
Tocilizumab monotherapy Variant #01 | — | R 9 664 | 14d | — | — | ~8 | ~R 77 309 indirect | — |
Bortezomib monotherapy Variant #03 | — | R 6 762 | 21d | ~30.3 mo | — | ~8 | ~R 54 096 PFS proxy · indirect | 5 |
TCP Variant #01 | — | R 2 166 | 7d | — | — | ~104 | ~R 221 068 indirect | — |
Sirolimus monotherapy Variant #01 | — | R 484 | — | — | — | ~1 | ~R 484 indirect | — |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~20.3 mo | — | ~1 | — | 20 |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Anakinra monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
9 of 9 regimens shown